PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security

PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S.
Department of Homeland Security

ANNAPOLIS, Md., Oct. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex:
PIP), a biodefense company developing medical countermeasures against
biological and chemical threats, today announced that company President and
Chief Executive Officer, David P. Wright and Dr. Valerie Riddle, Vice
President and Medical Director, were featured in the Homeland Security
Television Channel (HSTV) 30-minute documentary training video entitled,
"Deadly Pathogen: Exploring the Anthrax Threat," which was distributed to
65,000 members of the U.S. Department of Homeland Security.

The HSTV Deadly Pathogen documentary video provides an in-depth analysis of
the biological agent, Bacillus Anthracis, the bacteria that causes anthrax,
and details what this deadly pathogen does to the human body and why it
remains such an imminent threat to the security of millions of people
worldwide.

The training video was broadcast on the HSTV Threat Matrix Show that
investigates current trends and issues in Homeland Security. The show takes
an investigative approach to the policy and technology challenges and emerging
threats facing the homeland security community.

"We are delighted to share our expertise with the U.S. Department of Homeland
Security on anthrax weaponization, anthrax disease pathogenesis, and
promising, second generation vaccine product candidates to address this
biological threat," commented David P. Wright. "PharmAthene is developing a
second generation recombinant protective antigen (rPA) anthrax vaccine called
SparVax(TM) to protect civilians and the military and to advance our company
goal of becoming the leading provider of best-in-class medical countermeasures
for the biodefense industry."

The HSTV Deadly Pathogen: Exploring the Anthrax Threat 30-minute documentary
video can be viewed on the link below.
http://www.hstvchannel.com/ThreatMatrix/Deadly_Pathogen_Anthrax.html

Homeland Security Television Channel
The Homeland Security Television Channel (HSTV) is the world's first online,
on-demand television network dedicated to homeland security and global
development. HSTV is a 24/7 interactive television channel dedicated to
producing broadcast-quality video programs on all aspects of homeland security
and the role of global development in fighting terrorism.
http://www.hstvchannel.com

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its
allies by developing and commercializing medical countermeasures against
biological and chemical weapons. PharmAthene's lead product development
programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim® - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection

-- Protexia® - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
agents

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including statements
proceeded by, followed by, or that include the words "potential"; "believe";
"anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may";
"should"; or similar statements are forward-looking statements. PharmAthene
disclaims, however, any intent or obligation to update these forward-looking
statements. Risks and uncertainties include risk associated with the
reliability of the results of the studies relating to human safety and
possible adverse effects resulting from the administration of the Company's
product candidates, unexpected funding delays and/or reductions or elimination
of U.S. government funding for one or more of the Company's development
programs, including without limitation our bid related to SparVax(TM) under
the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen
(rPA) Vaccine for the Strategic National Stockpile, the award of government
contracts to our competitors, unforeseen safety issues, challenges related to
the development, scale-up, technology transfer, and/or process validation of
manufacturing processes for our product candidates, unexpected determinations
that these product candidates prove not to be effective and/or capable of
being marketed as products, as well as risks detailed from time to time in
PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its
other reports filed with the U.S. Securities and Exchange Commission (the
"SEC").

Copies of PharmAthene's public disclosure filings are available from its
investor relations department and our website under the investor relations tab
at www.PharmAthene.com.

SOURCE PharmAthene, Inc.

Stacey Jurchison, PharmAthene, Inc., +1-410-269-2610,
Stacey.Jurchison@PharmAthene.com